Trial Outcomes & Findings for Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma (NCT NCT03513952)
NCT ID: NCT03513952
Last Updated: 2024-07-26
Results Overview
ORR is defined as the proportion of patients who have achieved Complete Response (CR) - disappearance of all target lesions or Partial Response (PR) - \>=30% decrease in the sum of the longest diameter of target lesions according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; Overall Response (OR) = CR + PR.
Recruitment status
COMPLETED
Study phase
PHASE2
Target enrollment
47 participants
Primary outcome timeframe
Up to 2 years
Results posted on
2024-07-26
Participant Flow
Safety Run-In Phase: If the treatment combination demonstrates an acceptable safety profile (one or fewer patient experiences a protocol-defined Dose Limiting-Toxicity), randomized enrollment will begin.
Participant milestones
| Measure |
Group 1 (CYT107, Atezolizumab)
Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
Glycosylated Recombinant Human Interleukin-7: Given IM
|
Group 2 (Atezolizumab)
Patients receive atezolizumab on Day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
|
Safety Run in Phase
Patients were not randomized; they were assigned to the experimental arm treatment (atezolizumab + CYT107). Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
Glycosylated Recombinant Human Interleukin-7: Given IM
|
|---|---|---|---|
|
Overall Study
STARTED
|
19
|
21
|
7
|
|
Overall Study
COMPLETED
|
3
|
2
|
0
|
|
Overall Study
NOT COMPLETED
|
16
|
19
|
7
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
Baseline characteristics by cohort
| Measure |
Group 1 (CYT107, Atezolizumab)
n=19 Participants
Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
Glycosylated Recombinant Human Interleukin-7: Given IM
|
Group 2 (Atezolizumab)
n=21 Participants
Patients receive atezolizumab on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
|
Safety Run in Phase
n=7 Participants
Patients were not randomized; they were assigned to the experimental arm treatment (atezolizumab + CYT107). Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
Glycosylated Recombinant Human Interleukin-7: Given IM
|
Total
n=47 Participants
Total of all reporting groups
|
|---|---|---|---|---|
|
Age, Continuous
|
65.7 years
STANDARD_DEVIATION 9.2 • n=5 Participants
|
66.3 years
STANDARD_DEVIATION 8.5 • n=7 Participants
|
59.7 years
STANDARD_DEVIATION 11 • n=5 Participants
|
65.1 years
STANDARD_DEVIATION 9.3 • n=4 Participants
|
|
Sex: Female, Male
Female
|
3 Participants
n=5 Participants
|
5 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
9 Participants
n=4 Participants
|
|
Sex: Female, Male
Male
|
16 Participants
n=5 Participants
|
16 Participants
n=7 Participants
|
6 Participants
n=5 Participants
|
38 Participants
n=4 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=5 Participants
|
2 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
2 Participants
n=4 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
19 Participants
n=5 Participants
|
19 Participants
n=7 Participants
|
6 Participants
n=5 Participants
|
44 Participants
n=4 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
1 Participants
n=5 Participants
|
1 Participants
n=4 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=5 Participants
|
3 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
3 Participants
n=4 Participants
|
|
Race (NIH/OMB)
White
|
19 Participants
n=5 Participants
|
18 Participants
n=7 Participants
|
7 Participants
n=5 Participants
|
44 Participants
n=4 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=4 Participants
|
|
Region of Enrollment
United States
|
19 Participants
n=5 Participants
|
21 Participants
n=7 Participants
|
7 Participants
n=5 Participants
|
47 Participants
n=4 Participants
|
PRIMARY outcome
Timeframe: Up to 2 yearsORR is defined as the proportion of patients who have achieved Complete Response (CR) - disappearance of all target lesions or Partial Response (PR) - \>=30% decrease in the sum of the longest diameter of target lesions according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; Overall Response (OR) = CR + PR.
Outcome measures
| Measure |
Group 1 (CYT107, Atezolizumab)
n=19 Participants
Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
Glycosylated Recombinant Human Interleukin-7: Given IM
|
Group 2 (Atezolizumab)
n=21 Participants
Patients receive atezolizumab on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
|
Safety Run in Phase
n=7 Participants
Patients were not randomized; they were assigned to the experimental arm treatment (atezolizumab + CYT107). Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
Glycosylated Recombinant Human Interleukin-7: Given IM
|
|---|---|---|---|
|
Objective Response Rate (ORR)
Partial Response (PR)
|
3 Participants
|
4 Participants
|
0 Participants
|
|
Objective Response Rate (ORR)
Complete Response (CR)
|
2 Participants
|
1 Participants
|
0 Participants
|
|
Objective Response Rate (ORR)
Combined total PR + CR
|
5 Participants
|
5 Participants
|
0 Participants
|
SECONDARY outcome
Timeframe: Up to 2 yearsPopulation: The PD-L1 assay produced no data due to expired antibody. Stratification by PD-L1 expression levels in the tumor microenvironment cannot be reported.
CBR is defined as the percentage of patients with advanced or metastatic cancer who have achieved CR (disappearance of all target lesions), PR (\>=30% decrease in the sum of the longest diameter of target lesions), and stable disease (SD) (neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum diameters of target lesions) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1; CBR = CR + PR + SD. Will also assess CBR in patients stratified by PD-L1 expression levels in the tumor microenvironment.
Outcome measures
| Measure |
Group 1 (CYT107, Atezolizumab)
n=19 Participants
Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
Glycosylated Recombinant Human Interleukin-7: Given IM
|
Group 2 (Atezolizumab)
n=21 Participants
Patients receive atezolizumab on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
|
Safety Run in Phase
n=7 Participants
Patients were not randomized; they were assigned to the experimental arm treatment (atezolizumab + CYT107). Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
Glycosylated Recombinant Human Interleukin-7: Given IM
|
|---|---|---|---|
|
Clinical Benefit Rate (CBR) Measured by RECIST v1.1
Stable Disease (SD)
|
2 Participants
|
4 Participants
|
2 Participants
|
|
Clinical Benefit Rate (CBR) Measured by RECIST v1.1
Partial Response (PR)
|
3 Participants
|
4 Participants
|
0 Participants
|
|
Clinical Benefit Rate (CBR) Measured by RECIST v1.1
Complete Response (CR)
|
2 Participants
|
1 Participants
|
0 Participants
|
|
Clinical Benefit Rate (CBR) Measured by RECIST v1.1
Combined total CR + PR + SD
|
7 Participants
|
9 Participants
|
2 Participants
|
SECONDARY outcome
Timeframe: Time from start of treatment to time of progression or death, whichever occurs first, assessed up to 2 years.Population: Patients without documented PD or death are censored at the last disease assessment date. The PD-L1 assay produced no data due to expired antibody. Stratification by PD-L1 expression levels in the tumor microenvironment cannot be reported.
Progression is defined, per RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions (the sum must demonstrate an absolute increase of at least 5 mm), or the appearance of new lesions and/or unequivocal progression of non-target lesions. PFS will be summarized using Kaplan-Meier estimates. Will also assess PFS in patients stratified by PD-L1 expression levels in the tumor microenvironment.
Outcome measures
| Measure |
Group 1 (CYT107, Atezolizumab)
n=19 Participants
Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
Glycosylated Recombinant Human Interleukin-7: Given IM
|
Group 2 (Atezolizumab)
n=21 Participants
Patients receive atezolizumab on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
|
Safety Run in Phase
n=7 Participants
Patients were not randomized; they were assigned to the experimental arm treatment (atezolizumab + CYT107). Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
Glycosylated Recombinant Human Interleukin-7: Given IM
|
|---|---|---|---|
|
Progression-free Survival (PFS)
|
2.1 months
Interval 1.2 to 6.1
|
2.2 months
Interval 1.8 to 4.6
|
2.1 months
Interval 1.1 to 4.0
|
SECONDARY outcome
Timeframe: Time interval between the date of first response (CR/PR) and the date of progression, assessed up to 2 years.Population: The PD-L1 assay produced no data due to expired antibody. Stratification by PD-L1 expression levels in the tumor microenvironment cannot be reported.
DOR is measured by RECIST v1.1. DOR will be summarized using Kaplan-Meier estimates. Will also assess DOR in patients stratified by PD-L1 expression levels in the tumor microenvironment.
Outcome measures
| Measure |
Group 1 (CYT107, Atezolizumab)
n=19 Participants
Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
Glycosylated Recombinant Human Interleukin-7: Given IM
|
Group 2 (Atezolizumab)
n=21 Participants
Patients receive atezolizumab on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
|
Safety Run in Phase
Patients were not randomized; they were assigned to the experimental arm treatment (atezolizumab + CYT107). Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
Glycosylated Recombinant Human Interleukin-7: Given IM
|
|---|---|---|---|
|
Duration of Response (DOR)
|
NA months
Interval 2.3 to
The medians and 95% CIs for DOR were calculated based on Kaplan-Meier estimates. The Kaplan-Meier curve does not cross the 50% probability; therefore, the median survival time could not be calculated. Insufficient events to calculate a reliable upper 95% CI.
|
NA months
Interval 4.0 to
The medians and 95% CIs for DOR were calculated based on Kaplan-Meier estimates. The Kaplan-Meier curve does not cross the 50% probability; therefore, the median survival time could not be calculated. Insufficient events to calculate a reliable upper 95% CI.
|
—
|
SECONDARY outcome
Timeframe: Time interval between start of treatment to death due to any cause, assessed up to 48 months.Population: The PD-L1 assay produced no data due to expired antibody. Stratification by PD-L1 expression levels in the tumor microenvironment cannot be reported.
OS will be summarized using Kaplan-Meier estimates. Will also assess OS in patients stratified by PD-L1 expression levels in the tumor microenvironment.
Outcome measures
| Measure |
Group 1 (CYT107, Atezolizumab)
n=19 Participants
Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
Glycosylated Recombinant Human Interleukin-7: Given IM
|
Group 2 (Atezolizumab)
n=19 Participants
Patients receive atezolizumab on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
|
Safety Run in Phase
n=7 Participants
Patients were not randomized; they were assigned to the experimental arm treatment (atezolizumab + CYT107). Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
Glycosylated Recombinant Human Interleukin-7: Given IM
|
|---|---|---|---|
|
Overall Survival (OS)
|
9.1 months
Interval 2.6 to
The medians and 95% CIs for OS were calculated based on Kaplan-Meier estimates. Insufficient events to calculate a reliable upper 95% CI.
|
10.4 months
Interval 4.7 to 20.7
|
4.5 months
Interval 1.1 to 9.8
|
OTHER_PRE_SPECIFIED outcome
Timeframe: Up to 2 yearsThe evaluation of the effect of the investigation treatment combination on the immune-bias of the tumor microenvironment, based upon baseline and post-baseline tumor biopsy comparisons of number, distribution, and phenotype of tumor-infiltrating cells; PD-L1 expression, and expression of Interferon gamma (IFN-gamma) and associated proinflammatory gene expression in the tumor microenvironment.
Outcome measures
Outcome data not reported
Adverse Events
Group 1 (CYT107, Atezolizumab)
Serious events: 13 serious events
Other events: 18 other events
Deaths: 11 deaths
Group 2 (Atezolizumab)
Serious events: 11 serious events
Other events: 19 other events
Deaths: 14 deaths
Safety Run in Phase
Serious events: 5 serious events
Other events: 7 other events
Deaths: 6 deaths
Serious adverse events
| Measure |
Group 1 (CYT107, Atezolizumab)
n=19 participants at risk
Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
Glycosylated Recombinant Human Interleukin-7: Given IM
|
Group 2 (Atezolizumab)
n=19 participants at risk
Patients receive atezolizumab on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
|
Safety Run in Phase
n=7 participants at risk
Patients were not randomized; they were assigned to the experimental arm treatment (atezolizumab + CYT107). Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
Glycosylated Recombinant Human Interleukin-7: Given IM
|
|---|---|---|---|
|
Blood and lymphatic system disorders
Anemia
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
15.8%
3/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Cardiac disorders
Atrial Flutter
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Cardiac disorders
Myocardial Infarction
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Gastrointestinal disorders
Colitis
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Gastrointestinal disorders
Esophageal Obstruction
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Gastrointestinal disorders
Nausea
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Gastrointestinal disorders
Small Intestinal Obstruction
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
Death NOS
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
Disease Progression
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
Edema Limbs
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
Fatigue
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
Fever
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
Generalized Edema
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
Non-Cardiac Chest Pain
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Infections and infestations
Enterocolitis Infectious
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Infections and infestations
Lung Infection
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Infections and infestations
Sepsis
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Infections and infestations
Upper Respiratory Infection
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Infections and infestations
Urinary Tract Infection
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Alanine Aminotransferase Increased
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Aspartate Aminotransferase Increased
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Blood Bilirubin Increased
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Creatinine Increased
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Lipase Increased
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Serum Amylase Increased
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Metabolism and nutrition disorders
Hypercalcemia
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Metabolism and nutrition disorders
Hyperkalemia
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Metabolism and nutrition disorders
Hyponatremia
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Back Pain
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Bone Pain
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Flank Pain
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Generalized Muscle Weakness
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Progressive Disease
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Nervous system disorders
Concentration Impairment
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Nervous system disorders
Encephalopathy
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Nervous system disorders
Peripheral Motor Neuropathy
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Nervous system disorders
Stroke
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Nervous system disorders
Syncope
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Renal and urinary disorders
Acute Kidney Injury
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
15.8%
3/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Renal and urinary disorders
Acute Tubular Necrosis
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Renal and urinary disorders
Cystitis Noninfective
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Renal and urinary disorders
Hematuria
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Renal and urinary disorders
Urinary Retention
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Renal and urinary disorders
Urinary Tract Obstruction
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Renal and urinary disorders
Urosepsis
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Reproductive system and breast disorders
Pelvic Pain
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Respiratory, thoracic and mediastinal disorders
Hypoxia
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Vascular disorders
Deep Vein Thrombosis
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Vascular disorders
Hypotension
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Vascular disorders
Thromboembolic Event
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
Other adverse events
| Measure |
Group 1 (CYT107, Atezolizumab)
n=19 participants at risk
Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
Glycosylated Recombinant Human Interleukin-7: Given IM
|
Group 2 (Atezolizumab)
n=19 participants at risk
Patients receive atezolizumab on day 1 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
|
Safety Run in Phase
n=7 participants at risk
Patients were not randomized; they were assigned to the experimental arm treatment (atezolizumab + CYT107). Patients receive CYT107 on days 1, 8, 15, and 22, and atezolizumab on day 8 of cycle 1. Following cycle 1, patients receive atezolizumab on day 1. Cycles with atezolizumab repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity.
Atezolizumab: Given IV
Glycosylated Recombinant Human Interleukin-7: Given IM
|
|---|---|---|---|
|
Infections and infestations
Urinary Tract Infection
|
21.1%
4/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Blood and lymphatic system disorders
Anemia
|
36.8%
7/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
42.1%
8/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
42.9%
3/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Blood and lymphatic system disorders
DVT
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Blood and lymphatic system disorders
Eosinophilia
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Blood and lymphatic system disorders
Hypervolemia
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Cardiac disorders
Chest Pain - Cardiac
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Cardiac disorders
Diastolic Dysfunction
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Cardiac disorders
Heart Failure
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Cardiac disorders
Sinus Bradycardia
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Cardiac disorders
Sinus Tachycardia
|
15.8%
3/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Cardiac disorders
Supraventricular Tachycardia
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Ear and labyrinth disorders
Ear Pain
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Ear and labyrinth disorders
Right Ear Impaction
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Endocrine disorders
Hyperparathyroidism
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Endocrine disorders
Hypothyroidism
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Eye disorders
Blurred Vision
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Eye disorders
Floaters
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Eye disorders
Itchy Eyes
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Eye disorders
Tunnel Vision
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Gastrointestinal disorders
Abdominal Pain
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
36.8%
7/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Gastrointestinal disorders
Anal Pain
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Gastrointestinal disorders
Ascites
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Gastrointestinal disorders
Bloating
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Gastrointestinal disorders
Colonic Obstruction
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Gastrointestinal disorders
Constipation
|
42.1%
8/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
31.6%
6/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Gastrointestinal disorders
Diarrhea
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
42.1%
8/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Gastrointestinal disorders
Dry Mouth
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Gastrointestinal disorders
Dyspepsia
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Gastrointestinal disorders
Dysphagia
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Gastrointestinal disorders
Esophageal Pain
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Gastrointestinal disorders
Fecal Incontinence
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Gastrointestinal disorders
Flatulence
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Gastrointestinal disorders
Gastroesophageal Reflux Disease
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Gastrointestinal disorders
Mucositis Oral
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Gastrointestinal disorders
Nausea
|
36.8%
7/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
15.8%
3/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
57.1%
4/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Gastrointestinal disorders
Toothache
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Gastrointestinal disorders
Vomiting
|
15.8%
3/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
57.1%
4/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
Bilateral Pulmonary Emboli
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
Chills
|
21.1%
4/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
28.6%
2/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
DVT
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
Edema Limbs
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
Fatigue
|
57.9%
11/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
42.1%
8/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
42.9%
3/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
Fever
|
21.1%
4/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
42.9%
3/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
Generalized Edema
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
Hydronephrosis
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
Hypochloremia
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
Increased Prothrombin
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
Injection Site Reaction
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
Non-Cardiac Chest Pain
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
Pain
|
15.8%
3/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
Physical Deconditioning
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
Redness at Injection Site
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
Shaking/Shivering
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
General disorders
Swelling at Injection Site
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Infections and infestations
Abdominal Infection
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Infections and infestations
Autoimmune Hepatitis
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Infections and infestations
Covid
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Infections and infestations
Lung Infection
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Infections and infestations
Oral Candidiasis
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Infections and infestations
Sepsis
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Infections and infestations
Skin Infection
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Infections and infestations
Tooth Infection
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Infections and infestations
Upper Respiratory Infection
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Injury, poisoning and procedural complications
Bruising
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Injury, poisoning and procedural complications
Fall
|
21.1%
4/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Injury, poisoning and procedural complications
Fracture
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Injury, poisoning and procedural complications
Hip Fracture
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Injury, poisoning and procedural complications
Infusion Related Reaction
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Injury, poisoning and procedural complications
Spinal Fracture
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Activated Partial Thromboplastin Time Prolonged
|
15.8%
3/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Alanine Aminotransferase Increased
|
21.1%
4/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Alkaline Phosphatase Increased
|
31.6%
6/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
15.8%
3/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
42.9%
3/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
aPTT Decreased
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Aspartate Aminotransferase Increased
|
21.1%
4/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
28.6%
2/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Blood Bilirubin Increased
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Blood Lactate Dehydrogenase Increased
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
BUN Increased
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
CD4 Lymphocytes Decreased
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
CD8 Lymphocytes Decreased
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Creatinine Increased
|
47.4%
9/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
31.6%
6/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
42.9%
3/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Elevated BUN
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Hemoglobin Increased
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Hypochloremia
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Increased BUN
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
INR Increased
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
21.1%
4/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Lactic Acid Increased
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
LDH Increased
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Lipase Increased
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Lymphocyte Count Decreased
|
15.8%
3/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
21.1%
4/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Lymphocyte Count Increased
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Monocytosis
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Neutrophil Count Decreased
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Neutrophilia
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Platelet Count Decreased
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
26.3%
5/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Prolonged Prothrombin Time
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Shoulder Pain
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Thrombocytosis
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Thyroid Stimulating Hormone Increased
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Total Protein Elevated
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
WBC Increased
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
Weight Loss
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Investigations
White Blood Cell Decreased
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
21.1%
4/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Metabolism and nutrition disorders
Anorexia
|
26.3%
5/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
26.3%
5/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Metabolism and nutrition disorders
Dehydration
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Metabolism and nutrition disorders
Hypercalcemia
|
15.8%
3/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Metabolism and nutrition disorders
Hyperglycemia
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
15.8%
3/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Metabolism and nutrition disorders
Hyperkalemia
|
26.3%
5/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Metabolism and nutrition disorders
Hypermagnesemia
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Metabolism and nutrition disorders
Hyperphosphatemia
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Metabolism and nutrition disorders
Hypoalbuminemia
|
31.6%
6/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
26.3%
5/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Metabolism and nutrition disorders
Hypocalcemia
|
15.8%
3/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Metabolism and nutrition disorders
Hypokalemia
|
15.8%
3/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
21.1%
4/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Metabolism and nutrition disorders
Hypomagnesemia
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
28.6%
2/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Metabolism and nutrition disorders
Hyponatremia
|
36.8%
7/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
36.8%
7/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Metabolism and nutrition disorders
Hypophosphatemia
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
15.8%
3/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
15.8%
3/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Back Pain
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
28.6%
2/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Bone Pain
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Chest Wall Pain
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Flank Pain
|
21.1%
4/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Generalized Muscle Weakness
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Joint Range of Motion Decreased
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Muscle Cramp
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Muscle Weakness Lower Limb
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Neck Pain
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Pain in Extremity
|
15.8%
3/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Rotator Cuff Injury
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Musculoskeletal and connective tissue disorders
Trigger Finger, Left Hand
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Brain Mets
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Nervous system disorders
Dizziness
|
15.8%
3/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Nervous system disorders
Dysgeusia
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Nervous system disorders
Encephalopathy
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Renal and urinary disorders
Urinary Incontinence
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Nervous system disorders
Headache
|
31.6%
6/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Nervous system disorders
Memory Impairment
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Nervous system disorders
Neuralgia
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Nervous system disorders
Paresthesia
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Nervous system disorders
Peripheral Motor Neuropathy
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Nervous system disorders
Peripheral Sensory Neuropathy
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Nervous system disorders
Spasticity
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Psychiatric disorders
Anxiety
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Psychiatric disorders
Confusion
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Psychiatric disorders
Depression
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Psychiatric disorders
Distracted and Forgetful
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Psychiatric disorders
Insomnia
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Renal and urinary disorders
Acute Kidney Injury
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Renal and urinary disorders
Bladder Spasm
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Renal and urinary disorders
Chronic Kidney Disease
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Renal and urinary disorders
Dysuria
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Renal and urinary disorders
Hematuria
|
15.8%
3/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Renal and urinary disorders
Hydroneprosis
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Renal and urinary disorders
Nephrostomy Dislodgment
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Renal and urinary disorders
Nocturia - Intermittent
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Renal and urinary disorders
Renal Injury
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Renal and urinary disorders
Urinary Tract Obstruction
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Renal and urinary disorders
Urinary Urgency
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Renal and urinary disorders
Urine Discoloration
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Reproductive system and breast disorders
Pelvic Pain
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Reproductive system and breast disorders
Perineal Pain
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Respiratory, thoracic and mediastinal disorders
Allergic Rhinitis
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Respiratory, thoracic and mediastinal disorders
Aspiration
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
21.1%
4/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnea
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
28.6%
2/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural Effusion
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Respiratory, thoracic and mediastinal disorders
Sore Throat
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Respiratory, thoracic and mediastinal disorders
Wheezing
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Dry Skin
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Eczema
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Hyperhidrosis
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Hyperkeratosis
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Itching and Discomfort Around Ostomy/Stoma
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Night Sweats
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Ostomy/Stome
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Pain of Skin
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Photosensitivity
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Possible Folliculitis/Rash Around Stoma
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
26.3%
5/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Rash Acneiform
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
28.6%
2/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Rash Maculo-Papular
|
21.1%
4/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
15.8%
3/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Skin Hyperpigmentation
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Skin Ulceration
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Slight Itch All Over Body
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Stoma/Ostomy
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Sun Burn Blisters
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Suspicious for SCC
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Skin and subcutaneous tissue disorders
Tissue Sloughing
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Vascular disorders
Hypertension
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
21.1%
4/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
28.6%
2/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Vascular disorders
Hypotension
|
21.1%
4/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Vascular disorders
Lymphedema
|
5.3%
1/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
|
Vascular disorders
Thromboembolic Event
|
10.5%
2/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
0.00%
0/19 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
14.3%
1/7 • Serious Adverse Events and other (not including serious) adverse events were assessed for up to 30 days post-treatment. All-cause mortality was assessed for up to 48 months.
Two patients randomized in Group 2 (Atezolizumab) did not receive any study treatment, therefore the total number of participants at risk in the Serious Adverse Events and other (not including serious) adverse events tables were adjusted accordingly.
|
Additional Information
Cancer Immunotherapy Trials Network Trial Manager
Fred Hutchinson Cancer Center
Phone: 514-718-2858
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: LTE60